SUN
PHARMA

December 15, 2021

National Stock Exchange of India Limited,	**BSE Limited,**
Exchange Plaza, 5th Floor,	Market Operations Dept.
Plot No. C/1, G Block,	P. J. Towers,
Bandra Kurla Complex,	Dalal Street,
Bandra (East), Mumbai- 400 051	Mumbai - 400 001
Scrip Symbol: SUNPHARMA	**Scrip Code: 524715**

Sub: Press Release

Dear Sir / Madam,

Please find enclosed herewith our Press Release relating to US FDA approval for generic Amphotericin B Liposome Injection, which we shall be releasing after sending this letter to you.

This is for your information and dissemination.

Thanking you,

Yours faithfully,
For **Sun Pharmaceutical Industries Limited**

Ashok I. Bhuta
Compliance Officer
Enclosed: As above

FOR IMMEDIATE RELEASE

Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection

Mumbai, India, December 15, 2021: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies), today announced that one of its wholly-owned subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. The generic product approval is based on AmBisome® Liposome for Injection, 50 mg/vial as a reference product.

Sun Pharma has been granted Competitive Generic Therapy (CGT) designation by US FDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for the product.

As per October 2021 IQVIA Health data, AmBisome® Liposome for Injection, 50mg/vial had annualized sales of approximately US$ 136 million in USA.

® - All brand names and trademarks are the property of respective owners

Disclaimer:
Statements in this Document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the interpretations of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter@SunPharma_Live.

Contacts

Investors		Media	
Nimish Desai		Gaurav Chugh	
Tel	+ 91 22 4324 4324, Ext 2778	Tel	+ 91 22 4324 4324, Ext 5373
Tel Direct	+ 91 22 43242778	Tel Direct	+ 91 22 43245373
Mobile	+ 91 98203 30182	Mobile	+ 91 98104 71414
E mail	nimish.desai@sunpharma.com	E mail	gaurav.chugh@sunpharma.com

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.